PMID- 34162404 OWN - NLM STAT- MEDLINE DCOM- 20211101 LR - 20220316 IS - 1756-8722 (Electronic) IS - 1756-8722 (Linking) VI - 14 IP - 1 DP - 2021 Jun 23 TI - A precision medicine classification for treatment of acute myeloid leukemia in older patients. PG - 96 LID - 10.1186/s13045-021-01110-5 [doi] LID - 96 AB - BACKGROUND: Older patients (>/= 60 years) with acute myeloid leukemia (AML) often have multiple, sequentially acquired, somatic mutations that drive leukemogenesis and are associated with poor outcome. Beat AML is a Leukemia and Lymphoma Society-sponsored, multicenter umbrella study that algorithmically segregates AML patients based upon cytogenetic and dominant molecular abnormalities (variant allele frequencies (VAF) >/= 0.2) into different cohorts to select for targeted therapies. During the conception of the Beat AML design, a historical dataset was needed to help in the design of the genomic algorithm for patient assignment and serve as the basis for the statistical design of individual genomic treatment substudies for the Beat AML study. METHODS: We classified 563 newly diagnosed older AML patients treated with standard intensive chemotherapy on trials conducted by Cancer and Leukemia Group B based on the same genomic algorithm and assessed clinical outcomes. RESULTS: Our classification identified core-binding factor and NPM1-mutated/FLT3-ITD-negative groups as having the best outcomes, with 30-day early death (ED) rates of 0 and 20%, respectively, and median overall survival (OS) of > 1 year and 3-year OS rates of >/= 20%. All other genomic groups had ED rates of 17-42%, median OS